Outcome of Patients With Low-Risk and Intermediate-1-Risk Myelodysplastic Syndrome After Hypomethylating Agent Failure A Report on Behalf of the MDS Clinical Research Consortium

BACKGROUND: The hypomethylating agents (HMAs) azacitidine and decitabine are most commonly used to treat patients with higher-risk myelodysplastic syndromes (MDS). To the authors' knowledge, the prognosis of patients with low-risk and intermediate-1– risk MDS by the International Prognostic Sco...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Jabbour, Elias J., Garcia-Manero, Guillermo, Strati, Paolo, Mishra, Asmita, Al Ali, Najla H., Padron, Eric, Lancet, Jeffrey, Kadia, Tapan, Daver, Naval, O'Brien, Susan, Steensma, David P., Sekeres, Mikkael A., Gore, Steven D., Dezern, Amy, Roboz, Gail J., List, Alan F., Kantarjian, Hagop M., Komrokji, Rami S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4378905/
https://ncbi.nlm.nih.gov/pubmed/25410759
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29145
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados